Accordingly, Luhtala et al [34], have been reported that cyclin E is frequently over-expressed but with limited prognostic or predictive value in HER-2-positive breast cancer irrespectively of trastuzumab therapy. This evidence concerns the gene CCNE1 and breast cancer.